Head-to-head comparisons of medication uses, side effects, warnings, and more.
Rinvoq (upadacitinib)
zeposia (ozanimod)
Rinvoq (upadacitinib)
zeposia (ozanimod)
Summary of Rinvoq vs. Zeposia
Summary for JAK inhibitor
Prescription only
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. It's used to treat certain inflammatory conditions, such as rheumatoid arthritis (RA), ulcerative colitis (UC), and eczema (atopic dermatitis). But it's not a first-choice option and typically only prescribed when other treatments haven't worked well. Rinvoq (upadacitinib) is taken by mouth, usually once daily. It's available as an extended-release tablet (Rinvoq) and an oral solution (Rinvoq LQ), but the two formulations aren't interchangeable. Side effects include a higher risk of infections, acne, and nausea.
Summary for Sphingosine 1-phosphate receptor modulator
Prescription only
Zeposia (ozanimod) is a sphingosine 1-phosphate (S1P) receptor modulator that's used to treat adults with ulcerative colitis (UC) or relapsing forms of multiple sclerosis (MS). It's a capsule that's taken by mouth, usually once per day (or as directed by your provider if you have certain liver problems). There are starter packs of the medication that help you slowly raise the dosage to a maintenance dosage over a week. Side effects typically depend on your medical condition, but generally include infections and changes in liver tests.
Indications of Rinvoq vs. Zeposia
Indications for
Moderate-to-severe inflammatory conditions in which other treatments haven't worked: